At present, there is an established clinical standard for treating joint disease: the total joint replacement. Yet, while the surgical devices and techniques used to implant them have been largely perfected, today’s standard replacement joints are very invasive, and not permanent. The lifespan of common replacement joints limits their effective use in patients aged 55 or older. This leaves patients between ages 18 and 55 suffering from cartilage damage, traumatic injury, or early stage cartilage loss with limited treatment options.
Nanochon, is developing an implant designed to not only replace lost and damaged cartilage, but also to encourage new tissue growth. Using 3-D printing and a novel material, the Nanochon implant is a sturdy medical advancement that is both an orthopedic load bearing implant as well a tissue growth scaffold. The Nanochon implant has the potential to deliver faster and more successful recoveries for patients, while reducing costs to health providers, payers, and patients. Nanochon’s aim is to set a new clinical standard for cartilage restoration.
-
Industry
-
Biotechnology Research
-
Company size
-
2-10 employees
-
Headquarters
-
Washington , DC
-
Type
-
Privately Held
-
Founded
-
2016
-
Specialties
-
sports medicine, orthopedics, medical devices, joint repair, cartilage , tissue engineering, and 3D printing
